Treatment with granulocytemacrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 3, 2010, Pages 164-171

  Schefold, Joerg C ^a   Zeden, Jan Philip ^b   Pschowski, Rene ^a   Hammoud, Ben ^a   Fotopoulou, Christina ^a   Hasper, Dietrich ^a   Fusch, Gerhard ^b   Haehling, Stephan Von ^a   Volk, Hans Dieter ^a   Meisel, Christian ^a   Schütt, Christine ^b   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 6; KYNURENIC ACID; KYNURENINE; PLACEBO; PROCALCITONIN; QUINOLINIC ACID; SEROTONIN; TRYPTOPHAN; CALCITONIN; IMMUNOLOGIC FACTOR; PROTEIN PRECURSOR;

ADULT; AMINO ACID BLOOD LEVEL; APACHE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; MALE; MORTALITY; PERITONITIS; PNEUMONIA; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; TREATMENT DURATION; TRYPTOPHAN METABOLISM; AGED; BIOSYNTHESIS; BLOOD; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CALCITONIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-DR ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; PLACEBOS; PROTEIN PRECURSORS; QUINOLINIC ACID; SEPSIS; SEROTONIN; SHOCK, SEPTIC; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 76649104745     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903405768     Document Type: Article

References (31)

1. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003;81:247-265
2. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309-379
3. Thackray SJ, Mowat CG, Chapman SK. Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans 2008;36:1120-1123
4. Zelante T, Fallarino F, Bistoni F, Puccetti P, Romani L. Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect 2009;11:133-141
5. Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, et al. Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation 2007;84(Suppl):S17-20.
6. Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 2009;15:1391-1396
7. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007;7:817-823
8. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-192
9. Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, et al. IDO expands human CD4-CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007;37:3054-3062
10. Ploder M, Spittler A, Schroecksnadel K, Neurauter G, Pelinka LE, Roth E, et al. Tryptophan degradation in multiple trauma patients: survivors compared with non-survivors. Clin Sci (Lond) 2009;116:593-598
11. Huttunen R, Syrjanen J, Aittoniemi J, Oja SS, Raitala A, Laine J, et al. High activity of indoleamine 2,3-dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 2009 May 18 [Epub ahead of print].
12. Logters TT, Laryea MD, Altrichter J, Sokolowski J, Cinatl J, Reipen J, et al. Increased plasma kynurenine values and kynurenine-tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 2009; 32:29-34.
13. Costantino G. New promises for manipulation of kynurenine pathway in cancer and neurological diseases. Expert Opin Ther Targets 2009;13:247-258
14. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment of autoimmune neuroInflammation with a synthetic tryptophan metabolite. Science 2005;310: 850-855
15. Tan P, Bharath A. Manipulation of indoleamine 2,3-dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opin Ther Targets 2009;13:987-1012.
16. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78.
17. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-891
18. Docke WD, Hofl ich C, Davis KA, Rottgers K, Meisel C, Kiefer P, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005;51: 2341-2347
19. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3: 678-681
20. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008;14:64-78.
21. Schefold JC, Hasper D, Volk HD, Reinke P. Sepsis: time has come to focus on the later stages. Med Hypotheses 2008;71: 203-208
22. Carr R, Brocklehurst P, Dore CJ, Modi N. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 2009;373:226-233
23. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. GM-CSF to reverse sepsis-associated immunosuppression: a double-blind randomized placebocontrolled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648
24. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003; 29:646-651
25. Schefold JC, von Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 2007;28:418-425
26. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008;8:533-544
27. Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009;24:1901-1908.
28. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941-952
29. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006;22:503-519, ix-x.
30. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005;77:3-15.
31. de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, et al. The Influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008;34:518-522